KEY DIAGNOSTIC TESTING MARKETS

This publication has been discontinued on July 19, 2011.

Introduction

Abstract

This TriMark Publications report reviews the high-growth market segments for clinical laboratory testing equipment and supplies in the clinical hospital market, using screening reagents and instruments for analysis of individual components in blood, serum or plasma. Further, it examines the subsections of each market segment, including the clinical laboratory and research areas. Activity and trends in the clinical diagnostic market are discussed, including the numbers of institutions using this type of testing, and the factors that influence purchasing activity. Discussion details the trends that have developed that stimulate this market, and offers detailed comments on the patterns of information processing in point-of-care (POC) testing instruments. The study surveys most of the important companies known to be marketing, manufacturing or developing instruments and reagents in the areas selected as high-growth diagnostic markets in the U.S. and worldwide. Each company is discussed in depth, with a section on its history, product line, business and marketing analysis, and a subjective commentary on the company' s position in its market and its strategic direction.

Table of Contents

1.Overview

• 1.1 Objective
• 1.2 Content and Scope
• 1.3 Methodology
• 1.4 Executive Summary

2. Introduction

• 2.1 Basic Structure and Perspectives
• 2.2 Global Diagnostic Products Industry Status and Prognosis
• 2.3 Size, Structure, and Growth of the Industry
  • 2.3.1 Current Market Size
  • 2.3.2 Market Segments
    • 2.3.2.1 Clinical Chemistry
    • 2.3.2.2 Immunoassays
    • 2.3.2.3 Nucleic Acid Arrays
    • 2.3.2.4 Coagulation Tests
• 2.4 Trends and Forces Driving the Industry
  • 2.4.1 Global Demographics
  • 2.4.2 Healthcare Delivery and Disease Management
  • 2.4.3 Technologic Innovation
• 2.5 Alternate Site Diagnostic Testing

3. Market Analysis

• 3.1 Glucose Monitoring
  • 3.1.1 Market Size
  • 3.1.2 Competitive Landscape
• 3.2 Rapid Coagulation Testing
• 3.3 Rapid Cardiac Markers
  • 3.3.1 Troponins
  • 3.3.2 BNP Testing
• 3.4 Drugs of Abuse Screening Testing
• 3.5 Infectious Disease Testing
  • 3.5.1 Campylobacter Species
  • 3.5.2 Chlamydia Species
  • 3.5.3 Clostridium difficile
  • 3.5.4 Cryptosporidium Species
  • 3.5.5 Dengue
  • 3.5.6 Entamoeba histolytica
  • 3.5.7 Giardia Species
  • 3.5.8 Helicobacter pylori
  • 3.5.9 Hepatitis Testing
    • 3.5.9.1 Overview
    • 3.5.9.2 Immunological Testing
      • 3.5.9.2.1 Hepatitis A (HAV)
      • 3.5.9.2.2 Hepatitis B (HBV)
      • 3.5.9.2.3 Hepatitis C (HCV)
      • 3.5.9.2.4 Hepatitis D (HDV)
      • 3.5.9.2.5 Hepatitis E
  • 3.5.10 HIV
  • 3.5.11 Rapid Influenza Testing
  • 3.5.12 Mononucleosis
  • 3.5.13 Rubella
  • 3.5.14 Salmonella Species
  • 3.5.15 Shiga-Toxin-Producing Escherichia coli
  • 3.5.16 Staphylococcus Species
  • 3.5.17 Streptococcus Species
  • 3.5.18 TB and Lyme Disease
• 3.6 Cholesterol Testing
• 3.7 Tumor Markers
  • 3.7.1 Market Description
  • 3.7.2 Clinical Diagnostic Serum Based Markers
  • 3.7.3 PSA Testing
  • 3.7.4 Other Markers

4. Business Trends

• 4.1 Industry Consolidation
• 4.2 Breath of Product Offering & Pricing
• 4.3 Government Regulation of Medical Devices
• 4.4 Clinical Laboratory Improvement Act (CLIA)
• 4.5 Reimbursement Issues

5. Patient Management Trends

• 5.1 Satellite Facilities
• 5.2 Point of Care Testing
• 5.3 In-Office Testing
• 5.4 Home Care Analysis
• 5.5 Non-traditional Methods for Sample Collecting

6. Technology Trends

• 6.1 Sensor Systems for Diagnostic Applications
• 6.2 Glucose Measurements
• 6.3 Cholesterol Testing
• 6.4 The New Workflow Paradigm
  • 6.4.1 Consolidated Workstations and Modularity
  • 6.4.2 Laboratory Automation & Robotics
  • 6.4.3 Laboratory Information Systems
• 6.5 Biosensor Technology
• 6.6 Protein Sequencing
• 6.7 DNA Sequencing
• 6.8 The Human Genome Project
• 6.9 Liquid Phase Chromatography
• 6.10 Polymerase Chain Reaction (PCR)
• 6.11 Capillary Electrophoresis
• 6.12 Proteomics

7. Alternate Site Testing: Hospital Issues

• 7.1 Moderators of Growth for Point of Care Testing
  • 7.1.1 Quality Assurance Issues
  • 7.1.2 Political Control
  • 7.1.3 Regulatory Requirements
  • 7.1.4 Finance
• 7.2 Attitudes of Critical Care Nurses and Physicians
• 7.3 Personnel for Point of Care Testing
• 7.4 Data Management Issues
  • 7.4.1 Wireless LANS
  • 7.4.2 Hospital Costs of Information Management
  • 7.4.3 Other Information Processing Capabilities
• 7.5 Patient Focused Outcome Measurements
• 7.6 Patient Care and Reimbursement
• 7.7 Decentralization Issues
• 7.8 Clinical Outcomes
• 7.9 Focused Testing
• 7.10 Satellite Facilities
• 7.11 Point of Care Testing

8. Strategic Assessments

• 8.1 Glucose Monitoring
• 8.2 Tumor Markers
• 8.3 Cardiac Markers
• 8.4 Infectious Disease Testing
• 8.5 Coagulation Testing
• 8.6 Drugs of Abuse Testing/Therapeutic Drug Monitoring

9. Market Trends & Forecasts

10. Corporate Directories

Related Reports